A blood-based colorectal cancer (CRC) screening test, SimpleScreen™, has shown a significant leap in performance, demonstrating high sensitivity for both malignant and advanced precancerous lesions ...
Despite popular belief, special purpose acquisition corporation (SPAC) mergers continue to take place Freenome and Perceptive Capital Solutions Corp resurrected the trend that saw several medical ...
Accomplished industry leader brings specialized experience to advance Freenome's screening blood tests for colorectal cancer, lung cancer and additional indications BRISBANE, Calif., April 8, 2025 ...
– Freenome building commercial infrastructure following recent CLIA lab certification and early access program for key health system partners, with new test launches for colorectal cancer, lung cancer ...
– Leading institutional investors commit $240 million through private investment in public equity (PIPE) led by Perceptive Advisors and RA Capital – – Freenome stockholders, PCSC shareholders and PIPE ...
Freenome is a biotechnology company pioneering an early cancer detection platform. (PRNewsfoto/Freenome Holdings, Inc.) By Freenome Holdings, Inc. – Leading institutional investors commit $240 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results